About / Team
Technology
Solutions
Knowledge Center
Collaborations
Contact
(844) 724-5204
info@genomeprofiling.com
News
We invite you to learn about the positive impact we are having.
News Articles
Nic Dracopoli, Ph.D. Joins GenPro’s Scientific Advisory Board
GenPro to Present at Biotech Showcase™ Annual Conference on January 9, 2018
GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017
GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients.
Genome Profiling’s CSO and Co-Founder, Dr. Adam Marsh, to Present at The Biomarker Conference in San Diego, February 18 – 19, 2016
Dr. Didier Landais joins Genome Profiling, LLC
Future for Epigenetic Breast Tumor Risk Screening
Citations
GenPro and Delaware’s Helen F. Graham Cancer Center Discover Novel EpiMarker
PharmaTech Outlook Selects GenPro to be among 2017’s Top 10
USA Today Reports on Christiana Care Collaboration with GenPro
GenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson’s Disease in blood.
Biotech Firm May Change Cancer Treatment With Early Testing
Startup Genpro Aims To Use Epigenetic Analysis Tech For Biomarker Discovery, Test Development
Press Releases
Genome Profiling, Fox Chase Cancer Center to Collaborate on Immune System Blood Test to Predict Checkpoint Inhibitor Response in Non-Small Cell Lung Cancer
Genome Profiling and Prominent Parkinson’s Disease Clinical Care and Research Center Commence Collaborative Research to Discover an Epigenetic Immune System Biomarker from Blood to Diagnose Early Stage Parkinson’s Disease
Genome Profiling Discovers Blood-Based Immune-System-Derived Epigenetic Biomarker that Predicts Responders vs Non-Responders to an Immune Checkpoint Therapy in a Solid Tumor Cancer
Genome Profiling Collaborates with Top 10 Biopharma and Discovers Novel Immune-System-Derived Liquid EpiMarker that Predicts Responders vs Non-Responders to Immune Checkpoint I-0 Therapy in Solid Tumor Cancer Patients
Matthew B. Stern, M.D. and Andre Ruzycky, Ph.D. Join Genome Profiling’s Scientific Advisory Board (SAB)
2019 Innovation Delaware
GenPro adds Two Esteemed Scientists to Scientific Advisory Board
GenPro Selected to Lead Epigenetic Profiling on Multi-Company Multi-Institution Team Formed to Discover New Precision Medicine Hypotheses for Undiagnosed Diseases
Dr. Adam Marsh, Genome Profiling’s CSO and Co-Founder, will present at the Eighth Annual Next Generation Dx Summit in Washington DC (August 22-26, 2016)
Dr. Adam Marsh of Genome Profiling, LLC to Present at the Cancer Diagnostics Conference in San Francisco on November 16, 2015